A cardiac-specific tetrapeptide bioregulator from the Khavinson series for heart tissue normalisation.
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) with proposed tissue-specific interaction with cardiac gene regulatory regions. Research from the St. Petersburg Institute suggests it normalises cardiomyocyte function, reduces oxidative stress in cardiac tissue, and may have protective effects against myocardial injury.
Part of the Khavinson short peptide bioregulator system. Cardiogen is used in Russian cardiology alongside conventional treatments as a supportive bioregulator. The primary scientific literature is from Russian institutions.
In the Khavinson bioregulator model, short peptides interact with gene promoter regions to normalise tissue-specific gene expression that has drifted with age or disease.